Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced hair thinning and was diagnosed with alopecia incognito and male pattern baldness. They are using minoxidil, finasteride, and dutasteride scalp injections, reporting gradual improvement with no side effects.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

A 23-year-old plans a hair transplant and uses finasteride, Essengen 6 Plus, ketoconazole shampoo, dermarolling, vitamins, and Foligain capsules. He seeks advice on his regimen and the timing of the procedure, considering family history and potential future hair loss.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

A 28-year-old underwent three hair transplants totaling 11,102 grafts at Eugenix, using finasteride and minoxidil to manage advanced hair loss. Despite limited density, the results are satisfactory, allowing the individual to feel presentable without a hat.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

A 19-year-old with rapid hair loss since 16 is considering a hair transplant but refuses to take finasteride or any 5α-Reductase inhibitors. They are currently using minoxidil, tretinoin, and microneedling with a Derminator 2, and only want hair until age 27.

A 21-year-old male has been experiencing hair thinning and receding since age 18 and is considering treatments like Minoxidil, finasteride, and RU58841. He regrets not starting treatment earlier.

A user shared their hair regrowth journey from age 21 to 25 using finasteride and a carnivore diet. Other users debated the effectiveness of diet changes versus genetic factors in hair loss.

A 21 year old who has been taking various treatments for hair loss such as dutasteride, RU58841, minoxidil and finasteride with no results. Other users share their experiences of dealing with hair loss at an early age and offer advice on how to cope.

The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.

A 21-year-old is using a topical solution with minoxidil and finasteride for hair loss, along with supplements and specific shampoos, and is considering switching to oral treatments if no progress is seen in a few months. They are concerned about diffuse thinning and potential future hair transplants, and are exploring additional treatments like microneedling and tretinoin.

JeremySoCa's DHT level was 29 ng/dl, considered low, and Estradiol was 26.1 pg/dl within the normal range. They are using topical finasteride for hair loss and had a thyroidectomy due to Graves' disease.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.

The conversation is about the availability of gt20029 for hair loss treatment, indicating that it will not be available for purchase soon. No specific treatments were discussed.

A user is considering switching from finasteride to dutasteride for hair loss at age 21, worried about potential side effects on bone and brain development. Another user shared their positive experience with dutasteride, noting minimal body hair and no side effects.

A discount code for 20% off at Anageninc is shared, valid for purchasing RU58841 or Pyri from May 10-11, 2025. The conversation focuses on hair loss treatments using RU58841.

A 21-year-old has started a hair loss routine using topical finasteride and minoxidil, Nioxin stage 4 products, and supplements like biotin. They are considering adding oral minoxidil but are advised to wait and see results first.

A 21-year-old is experiencing hair loss and is unable to use finasteride due to side effects, expressing frustration and depression. Others suggest topical DHT blockers like alfatradiol, spironolactone, and pyrilutamide, and mention using minoxidil and lifestyle changes.

The user is using dutasteride, oral minoxidil, and topical minoxidil with tretinoin for hair loss. They are considering whether to continue this treatment or opt for a hair transplant for their temples.

The conversation discusses the potential availability of GT20029 for hair loss treatment, with one user noting promising Phase 1 results and inquiring about gray market access. Another user humorously suggests it will take 50 years to become available.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

A 21-year-old has been using finasteride and minoxidil for 2.5 years without improvement in hair loss. They also tried RU58841, rosemary oil, and biotin, but none were effective.

A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.